Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
about
Light chain (AL) amyloidosis: update on diagnosis and managementCD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapyImmunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatmentUpdate on treatment of light chain amyloidosisAmyloid diseases of the heart: current and future therapiesLong-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.Amyloidosis and POEMS syndrome.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.Diagnosis and management of neuropathies associated with plasma cell dyscrasias.Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis.Kidney dysfunction during lenalidomide treatment for AL amyloidosis.Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trialAmyloidosis: pathogenesis and new therapeutic options.Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.Stabilisation of Laryngeal AL Amyloidosis with Long Term Curcumin Therapy.Lenalidomide Desensitization in Systemic Light-Chain Amyloidosis With Multi-Organ InvolvementActivity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.Cancer-testis antigen expression and immunogenicity in AL amyloidosis.Pharmacokinetics and tissue disposition of lenalidomide in mice.The amyloidoses: clinical features, diagnosis and treatment.Al amyloidosisThe evolving role of lenalidomide in the treatment of hematologic malignancies.Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trialA phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugsA Validated Stability-Indicating and Stereoselective HPLC Method for the Determination of Lenalidomide Enantiomers in Bulk Form and Capsules.Perspectives in treatment of AL amyloidosis.Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).Splenic plasma cells can serve as a source of amyloidogenic light chainsTreatment of plasma cell dyscrasias with lenalidomide.Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chainCurrent trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.
P2860
Q21198863-668893FF-F9F7-4BE2-A122-F5A764BE36A1Q24649764-2EF0196A-3156-4365-BDED-418501411809Q26827340-4AF8D062-5E60-4FED-985B-A10AB9D36A66Q26829735-6A7C9AAD-757B-4483-9B3B-F8C881A93E01Q27023836-1E4364B3-008E-4DAB-92A6-6DBCFEF82BD8Q33292965-5479B20B-2657-4119-83F2-7E0B474EA30CQ33304297-1D2F4036-128B-434D-AA7D-C7FF0C8FDDE5Q33802749-1A0AC390-15E1-4094-91A5-7238C7B61799Q33867198-D3CE3A67-610B-4C4A-8114-7E806EF8D864Q34253548-AEEEEB9D-C201-489E-A6A8-46337426CD87Q34353682-CC9B3B68-B440-4C00-8266-1877CC8ADDB4Q34448455-08385ECE-1FE2-479F-A82E-54D7E45FE07BQ34450910-0D2CFBC8-566F-4D3E-8FB6-8AD929CD2A0BQ34555067-436D6517-4857-4DD2-8397-4D8DDAE64624Q34768284-5158356B-F003-4AA2-BD9B-724E37C147D3Q35025410-2883D458-B27C-41DD-A0CA-7AED314A9154Q35081363-63E8F203-F276-43D7-85D5-FBAA963DB67DQ35111771-4366F0A2-C19E-411A-BAD9-C53CC65F7124Q35208216-FE7B1CCD-57A7-4490-8D14-F6CEAFCAEA3FQ35833408-AEAD3938-E888-486C-BEE3-1EA4EA4B6D8DQ36009723-0300AAE4-323C-451B-A2B9-0BDE506033B3Q36015183-29366CA7-1C9D-4637-8DE7-937F209A09A0Q36163205-9E868C5C-8BF5-4362-B3DB-6C0D6CDCC7C5Q36289604-C4DA185B-85AD-4FD6-9606-DEF88C5D9BC1Q36331493-9D39457E-5C91-40E7-B491-25E29374E887Q36366997-A6FAF83E-5044-40A5-8042-DE50A948E707Q36392233-4A3A5308-ADC1-425B-A2C1-6F64BF0335FAQ36739807-B693D2C5-E476-4984-8C36-8BF53D4B686BQ36779777-5B53A4B3-8912-4F1D-9889-0456DF1F8D34Q36805878-48EBDE5F-6F36-48FE-AB0E-2163C6976CE4Q36862339-9104C6B7-FD3F-43E6-B7CE-3FFACA1CB7D8Q36950813-CD931046-6447-43EB-B77C-EFF52872739CQ36960501-84D9A91C-D4BF-42FD-9182-D33AD3D73376Q37045885-EE833F8E-0BF7-4775-869E-EB575242522CQ37045900-EA2ADDB4-B223-4986-932D-4754DFE0CBAAQ37100733-425B211E-E651-4734-A37A-9D5DBBFE8BC8Q37176044-64C1158A-12D7-43D3-8596-73172D3F0FC7Q37212712-C9FFB1B2-DB47-4E80-BF90-68974ADE1020Q37284404-1A34F4AD-B79D-431F-A13B-4EE9832B2CB8Q37370051-DF594CE6-EEC2-4849-BC95-28F2F9122072
P2860
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Lenalidomide and dexamethasone ...... s: results of a phase 2 trial.
@ast
Lenalidomide and dexamethasone ...... s: results of a phase 2 trial.
@en
Lenalidomide and dexamethasone ...... s: results of a phase 2 trial.
@nl
type
label
Lenalidomide and dexamethasone ...... s: results of a phase 2 trial.
@ast
Lenalidomide and dexamethasone ...... s: results of a phase 2 trial.
@en
Lenalidomide and dexamethasone ...... s: results of a phase 2 trial.
@nl
prefLabel
Lenalidomide and dexamethasone ...... s: results of a phase 2 trial.
@ast
Lenalidomide and dexamethasone ...... s: results of a phase 2 trial.
@en
Lenalidomide and dexamethasone ...... s: results of a phase 2 trial.
@nl
P2093
P1433
P1476
Lenalidomide and dexamethasone ...... s: results of a phase 2 trial.
@en
P2093
Daniel G Wright
David C Seldin
Jerome B Zeldis
Kathleen T Finn
Martha Skinner
Michael Rosenzweig
Salli Fennessey
P304
P356
10.1182/BLOOD-2006-07-030544
P407
P577
2006-09-07T00:00:00Z